2015 Fiscal Year Final Research Report
Evaluation of serum ubiquitin enzyme as a new biomarker for PML-RARA leukemia
| Project/Area Number |
25460711
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Himeji Dokkyo University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIYAMOTO Kazuhide 姫路獨協大学, 薬学部, 准教授 (10415317)
SAIGO Katsuyasu 姫路獨協大学, 薬学部, 教授 (20304107)
TANIGUCHI Taizo 姫路獨協大学, 薬学部, 教授 (70346253)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | ユビキチン-プロテアソーム系 / PML/RARA / プロテアソーム阻害剤 / ERストレス |
|---|
| Outline of Final Research Achievements |
The ubiquitin-proteasome system (UPS) controls normal protein homeostasis in cells. Bortezomib, a proteasome inhibitor, time- and dose-dependently decreased cell viability and induced apoptosis in NB4, an acute promyelocytic leukemia (APL) cell line. We confirmed that UbcH8 is the E2-conjugating enzyme for a fusion protein PML-RARA. Moreover, UbcH8 abundance was dose-dependently increased in the culture supernatant of bortezomib-treated cells. Meanwhile, ER stress was increased by Bortezomib.
We concluded that Bortezomib impairs the UPS that controls normal protein homeostasis by causing excessive accumulation of PML-RARA fusion protein, augmenting ER stress and leading to APL cell death. Furthermore, monitoring of UPS-related enzymes can be used to predict the treatment response to proteasome inhibitors and assess their therapeutic effects.
|
| Free Research Field |
検査血液学
|
